New treatment for difficult-to-treat inflammato...( ability to shut down certain cancerous ...)

ability to shut down certain cancerous cells explains its effectiveness against leukemia. The HES patients received a much lower dose than is used in cancer treatment, however, suggesting eosinophils may contain a similar enzyme that is much more sensitive to the drug.

The low dosage also means people with HES may be able to keep their disease under control with a simple, inexpensive regimen. "The disease may be kept under control with two pills a week, compared to the four pills a day used to treat myelogenous leukemia," explains Dr. Gleich.

The study, though small, offers promise to people affected by HES. By highlighting how IL-5 and a potentially unknown enzyme might regulate eosinophils, the study also hints at new avenues for research. Says Dr. Gleich, "There is a crying need for a larger study."

'"/>

Contact: Sam Perdue
sp189u@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
2-May-2002

Page: 1 2
Related biology news :

1. Leader in cancer treatment and prevention research honored
2. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
3. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
4. New treatment for fibromyalgia
5. The impact of genetic variations on the treatment of early rheumatoid arthritis
6. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
7. Early clinical treatment can halt progression of Alzheimers disease, UCI researchers find
8. Colleagues to recognize research leadership in cancer detection, prevention and treatment
9. New view of leukemia cells identifies best treatment options, Stanford researchers say
10. Genetic model for devastating form of paraplegia suggests new treatments
11. Protective mechanism exploited by tumors may provide new cancer treatment